Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NT-I7 + Radiotherapy + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NT-I7 | GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin | NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516). | ||
Radiotherapy | ||||
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03687957 | Phase Ib/II | Radiotherapy + Temozolomide NT-I7 + Radiotherapy + Temozolomide | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-lymphopenic Gliomas Following Radiation and Temzolomide | Recruiting | USA | 0 |